Abstract
The RAS-RAF-MEK-ERK signaling pathway (ERK pathway) plays a key role in tumorigenesis and cancer progression. Mutations of RAS or B-RAF lead to a constitutive activation of the ERK pathway, which ultimately results in increased cell division, and cell survival. This review article focuses on the recent literature related to ERK pathway inhibitors, with a particular emphasis on RAF kinase inhibitors. Preclinical and clinical data for the RAF kinase inhibitor sorafenib (BAY 43-9006 tosylate), that was recently approved in the US for the treatment of advanced renal cell carcinoma, are also outlined.
Keywords: Sorafenib, BAY 43-9006, RAF-1, C-RAF, B-RAF, kinase inhibitor, MAP kinase
Current Topics in Medicinal Chemistry
Title: Recent Advances in the Research and Development of RAF Kinase Inhibitors
Volume: 6 Issue: 11
Author(s): Roger A. Smith, Jacques Dumas, Lila Adnane and Scott M. Wilhelm
Affiliation:
Keywords: Sorafenib, BAY 43-9006, RAF-1, C-RAF, B-RAF, kinase inhibitor, MAP kinase
Abstract: The RAS-RAF-MEK-ERK signaling pathway (ERK pathway) plays a key role in tumorigenesis and cancer progression. Mutations of RAS or B-RAF lead to a constitutive activation of the ERK pathway, which ultimately results in increased cell division, and cell survival. This review article focuses on the recent literature related to ERK pathway inhibitors, with a particular emphasis on RAF kinase inhibitors. Preclinical and clinical data for the RAF kinase inhibitor sorafenib (BAY 43-9006 tosylate), that was recently approved in the US for the treatment of advanced renal cell carcinoma, are also outlined.
Export Options
About this article
Cite this article as:
Smith A. Roger, Dumas Jacques, Adnane Lila and Wilhelm M. Scott, Recent Advances in the Research and Development of RAF Kinase Inhibitors, Current Topics in Medicinal Chemistry 2006; 6 (11) . https://dx.doi.org/10.2174/156802606777812077
DOI https://dx.doi.org/10.2174/156802606777812077 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Radiologic Findings of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy The Potential Protective Effect of Orange Peel and Selenium against 17β-Estradiol- Induced Chronic Non-Bacterial Prostatitis in Rats
Anti-Cancer Agents in Medicinal Chemistry Label-Free Cell Phenotypic Drug Discovery
Combinatorial Chemistry & High Throughput Screening Condition Optimization and Production of Extracellular l-Arginine Deiminase from Vibrio Alginolyticus 1374
Current Biotechnology Generation of a Chimeric Plasmin-resistant VEGF165/VEGF183 (132-158) Protein and its Comparative Activity
Protein & Peptide Letters Folate Based Radiopharmaceuticals for Imaging and Therapy of Cancer and Inflammation
Current Pharmaceutical Design Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism Peptide Aptamers: Development and Applications
Current Topics in Medicinal Chemistry Metabolomic Heterogeneity of Urogenital Tract Cancers Analyzed by Complementary Chromatographic Techniques Coupled with Mass Spectrometry
Current Medicinal Chemistry Overview of Coumarins and its Derivatives: Synthesis and Biological Activity
Letters in Organic Chemistry Novel and Emerging Drugs for Acute Myeloid Leukemia: Pharmacology and Therapeutic Activity
Current Medicinal Chemistry The Roles of Chromatin Remodeling Proteins in Cancer
Current Protein & Peptide Science Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates
Current Medicinal Chemistry Modulation of Cellular Response to Anticancer Treatment by Caffeine: Inhibition of Cell Cycle Checkpoints, DNA Repair and More
Current Pharmaceutical Biotechnology Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy 18F-Labeled Proteins
Current Pharmaceutical Biotechnology Antitumor Activity of Oxali-Titanocene Y in Xenografted CAKI-1 Tumors in Mice
Letters in Drug Design & Discovery